Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,444 across all filing types
Latest filing 2013-10-22 M&A Activity
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Imugene to acquire Biolife Science Qld Limited 3 pages 653.7KB
M&A Activity Classification · 95% confidence The document text prominently features the headline 'IMUGENE TO ACQUIRE BIOLIFE SCIENCE QLD LIMITED' indicating an acquisition announcement. The content appears to be an announcement or press release about a corporate transaction involving Imugene Limited acquiring another company. There is no indication of financial statements, audit information, regulatory certifications, or meeting materials. The document length is about 9,035 characters, which is sufficient for a detailed announcement but does not resemble a full annual or interim report. The focus on acquisition suggests it relates to merger and acquisition activity rather than a merger proxy statement or tender offer form. Therefore, the document is best classified under M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids.
2013-10-22 English
Presentation and Q&A - Acquisition of Biolife Science Qld 26 pages 4.0MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation about the acquisition of Biolife Science QLD Ltd by Imugene, focusing on the company's cancer immunotherapy assets, clinical trial phases, market opportunity, and investment highlights. It includes extensive information on the product, clinical trial design, market penetration models, and comparable drugs. There is no indication that this is a regulatory filing, audit report, earnings release, or any other formal financial report. The content is structured as an investor-focused presentation with strategic and financial highlights, clinical data, and market analysis. The document length is substantial (15,000 characters), and it is not merely an announcement or a brief summary. Therefore, the most appropriate classification is Investor Presentation (IP).
2013-10-22 English
Capital Raising Complete 1 page 89.2KB
Capital/Financing Update Classification · 90% confidence The document is titled 'CAPITAL RAISING COMPLETE' and contains limited text with many unreadable characters, but the key phrase indicates it is announcing the completion of a capital raising event. The document length is short (1453 characters), and there is no detailed financial data or comprehensive report content. This matches the description of a Capital/Financing Update, which covers updates on company fundraising or financing activities. Therefore, the document is best classified as a Capital/Financing Update (CAP).
2013-10-22 English
Notice of Annual General Meeting/Proxy Form 27 pages 690.7KB
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' and includes detailed agenda items for the 2013 Annual General Meeting of Imugene Limited. It contains resolutions to be voted on, including adoption of the Remuneration Report, election of directors, approval of share issues, and appointment of auditors. It also references the annual financial report and the 2013 Annual Report being available online but does not contain the full financial statements or detailed financial data itself. The document is a notice and explanatory statement for the AGM, not the actual annual report or financial statements. Therefore, it fits the category of AGM Information (AGM-R).
2013-10-20 English
Trading Halt 2 pages 242.6KB
Regulatory Filings Classification · 95% confidence The document is a market release announcing a trading halt requested by Imugene Limited pending an upcoming announcement related to a proposed acquisition and capital raising. It references ASX Listing Rule 17.1 and states the halt will remain until the announcement is released. The document does not contain financial data, detailed report content, or the actual announcement itself, but rather is a notice about the trading halt. This fits the category of a Regulatory Filing (RNS) as it is a compliance-related announcement that does not fit other specific categories like M&A filings or capital updates since the actual announcement is pending.
2013-10-20 English
Ceasing to be a substantial holder - JP 3 pages 29.0KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 under the Corporations Act 2001, titled 'Notice of ceasing to be a substantial holder.' It details changes in relevant interests and associations related to substantial shareholdings in Imugene Limited. The form includes dates, names, and shareholding changes but does not contain financial statements or company performance data. It is a regulatory notice about shareholding changes, specifically about ceasing to be a substantial holder, which fits the definition of a Major Shareholding Notification (MRQ). The document length (7302 characters) and content confirm it is not a brief announcement or a full financial report but a formal notification of shareholding changes.
2013-10-15 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.